Protagonist Therapeutics Inc diskutieren
Protagonist Therapeutics Inc
WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Aktie / Micro Cap /
82,00 €
0,61 %
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Neueste Beiträge
StockNews_com in Axcelis Technologies diskutieren